Politics / Law

Barroso wants to establish new Super EU Commissioner for biotech

30.11.2009

Brussels – John Dalli from Malta will be given almost all-important competencies, in the area of biotechnology in the next European Commission. The re-elected Commission President Manuel Barroso has concentrated a huge array of important responsibilities with Dalli who is to lead the DG Sanco. Dalli will take over liability for the European Medicines Agency (EMEA), and a cosmetics unit from DG Enterprise and Industry. The current Maltese Minister for Social Policy will take over all responsibilities for agribiotechnology - together with those relating to the European Food Safety Authority (EFSA) - from the DG Environment, which will now be led by the former Research Commissioner Janez Potocnik. In addition, Dalli will control the EU’s Plant Variety Office, the European Centre for Disease Control (ECDC), and will take over from Potocnik’s new authority the competencies for consumer protection, together with those for the Executive Agency for Health and Consumers (EAHC). The Maltese nationalist party member is thought to be a strong supporter of biotechnology, although his country is a blank spot on the biotech map. The new Commissioner for Health and Consumer Policy has told the media that “the ideal investment for his country should target biotech, pharma or electronics.” Barroso’s decision to give large biotech competencies to a single commissioner comes after conflicts over agribiotech in the former Commission between the GMO-supporting commissioners Verheugen (Industry), Fisher-Boel (Agriculture), Potocnik (Research), and the former GMO sceptical Environment Commissioner Stavros Dimas. Another important commissioner in the area of biotech will be Dacian Cilios. The former Romanian Minister for Agriculture oversaw decisions both backing GM maize and rejecting a GM potato. Furthermore, the new Research Commissioner Maire Geoghegan-Quinn will be overseeing the
Joint Research Centres (JRC), the European Research Council (ERC, and its executive agency ERCEA), as well as the Research Executive Agency (REA). The newly established Commissioner for Climate Action, Connie Hedegaard, will play an important role in branches of industrial biotech involved in the fermentation of renewable feedstocks and in the biotech production of carbon dioxide-consuming platform chemicals. Her new DG Climate Action has taken over most of the divisions of the previous Directorate C of Potocnik’s DG Environment. Information on all the new commissioners-to-be can be found here. The new Commission must next gain approval from the European Parliament before taking office for a term running until 31 October 2014. The vote of consent on the new Commission as a whole is expected to take place on 26 January. The Commission will be appointed by the European Council on the basis of this vote, at which point it will finally begin work.



Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/barroso-wants-to-establish-new-super-eu-commissioner-for-biotech.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.84 EUR4.80%
  • VITA 343.98 EUR4.19%
  • MEDIGENE4.07 EUR2.26%

FLOP

  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.24 CHF-4.00%
  • BASILEA97.25 CHF-1.22%

TOP

  • SANTHERA93.80 CHF46.3%
  • CO.DON2.84 EUR19.3%
  • FORMYCON8.22 EUR18.8%

FLOP

  • EVOTEC3.09 EUR-17.6%
  • MEDIGENE4.07 EUR-13.8%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA93.80 CHF2498.3%
  • CO.DON2.84 EUR234.1%
  • PAION2.69 EUR153.8%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.08 CHF-42.9%
  • 4SC1.16 EUR-40.5%

No liability assumed, Date: 14.09.2014


Current issue

All issues

Product of the week

Products